Lapatinib

Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007 Jul 5; 357(1): 39–51
Article PubMed CAS Google Scholar
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006 Dec 28; 355(26): 2733–43
Article PubMed CAS Google Scholar
Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004 Aug; 6(2): 117–27
Article PubMed CAS Google Scholar
Xia W, Gerard CM, Liu L, et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005 Sep 15; 24(41): 6213–21
Article PubMed CAS Google Scholar
Di Leo A, Gomez H, Aziz Z, et al. Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: a phase III randomized, double-blind study of 580 patients [abstract no. 1011 plus poster]. 43rd American Society of Clinical Oncology Annual Meeting; 2007 Jun 1–5; Chicago (IL)

Author information

Department of Medicine, University of California, Los Angeles, California, USA
Gottfried E. Konecny

Authors

Gottfried E. Konecny
View author publications
You can also search for this author in PubMed Google Scholar

Konecny, G.E. Lapatinib. Drugs 67, 2109–2110 (2007). https://doi.org/10.2165/00003495-200767140-00010

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.